Advanced search
Publication Cover
Clinical Ophthalmology Volume 18, 2024 - Issue
Submit an article Journal homepage
146
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States

Savak Teymoorian1 Harvard Eye Associates, Laguna Hills, CA, USACorrespondence[email protected]
View further author information
,
E Randy Craven2 Allergan, an AbbVie company, Irvine, CA, USAORCID Iconhttps://orcid.org/0000-0002-2077-659XView further author information
ORCID Icon,
Lannhi Nguyen1 Harvard Eye Associates, Laguna Hills, CA, USAView further author information
&
Erica Werts2 Allergan, an AbbVie company, Irvine, CA, USAView further author information
Pages 187-199 | Received 16 Oct 2023, Accepted 03 Jan 2024, Published online: 18 Jan 2024

References

  • Medeiros FA, Sheybani A, Shah MM, et al. Single administration of intracameral bimatoprost implant 10 µg in patients with open-angle glaucoma or ocular hypertension. Ophthalmol Ther. 2022;11(4):1517–1537. doi:10.1007/s40123-022-00527-6
  • Weinreb RN, Bacharach J, Brubaker JW, et al. Bimatoprost implant biodegradation in the phase 3, randomized, 20-month ARTEMIS studies. J Ocul Pharmacol Ther. 2023;39(1):55–62. doi:10.1089/jop.2022.0137
  • Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–1641. doi:10.1016/j.ophtha.2020.06.018
  • Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27(10):2043–2053. doi:10.1007/s11095-010-0159-x
  • Bacharach J, Tatham A, Ferguson G, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81(17):2017–2033. doi:10.1007/s40265-021-01624-9
  • Craven ER, Walters T, Christie WC, et al. 24-Month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 2020;80(2):167–179. doi:10.1007/s40265-019-01248-0
  • Lee SS, Dibas M, Almazan A, Robinson MR. Dose-response of intracameral bimatoprost sustained-release implant and topical bimatoprost in lowering intraocular pressure. J Ocul Pharmacol Ther. 2019;35(3):138–144. doi:10.1089/jop.2018.0095
  • Weinreb RN, Robinson MR, Dibas M, Stamer WD. Matrix metalloproteinases and glaucoma treatment. J Ocul Pharmacol Ther. 2020;36(4):208–228. doi:10.1089/jop.2019.0146
  • Stamer WD, Perkumas KM, Kang MH, Dibas M, Robinson MR, Rhee DJ. Proposed mechanism of long-term intraocular pressure lowering with the bimatoprost implant. Invest Ophthalmol Vis Sci. 2023;64(3):15. doi:10.1167/iovs.64.3.15
  • Weinreb RN, Christie WC, Medeiros FA, et al. Single administration of bimatoprost implant: effects on 24-hour intraocular pressure and 1-year outcomes. Ophthalmol Glaucoma. 2023;6(6):599–608. doi:10.1016/j.ogla.2023.06.007
  • Xu W, Zhou P, Kansara ND, Frankfort BJ, Blieden LS, Chang PT. Intraocular pressure and eyedrop usage reduction with intracameral bimatoprost implant. J Ocul Pharmacol Ther. 2023;39(6):398–403. doi:10.1089/jop.2023.0013
  • Liebmann JM, Barton K, Weinreb RN, et al. Evolving guidelines for intracameral injection. J Glaucoma. 2020;29 Suppl 1:S1–S7. doi:10.1097/IJG.0000000000001451
  • Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953–961. doi:10.1016/j.ophtha.2004.12.035
  • Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–740. doi:10.18553/jmcp.2009.15.9.728
  • Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye. 2000;14(Pt 5):752–756. doi:10.1038/eye.2000.197
  • Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118(12):2398–2402. doi:10.1016/j.ophtha.2011.05.013
  • Lewis RA, Christie WC, Day DG, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trial. Am J Ophthalmol. 2017;175:137–147. doi:10.1016/j.ajo.2016.11.020
  • Garg A, Gazzard G. Selective laser trabeculoplasty: past, present, and future. Eye. 2018;32(5):863–876. doi:10.1038/eye.2017.273
  • Chi SC, Kang YN, Hwang DK, Liu CJ. Selective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials. Br J Ophthalmol. 2020;104(11):1500–1507. doi:10.1136/bjophthalmol-2019-315613
  • Jang HJ, Yu B, Hodge W, Malvankar-Mehta MS. Repeat selective laser trabeculoplasty for glaucoma patients: a systematic review and meta-analysis. J Curr Glaucoma Pract. 2021;15(3):117–124. doi:10.5005/jp-journals-10078-1302
  • Wong MK, Bowers ME, Ventimiglia J, et al. Short-term outcomes of bimatoprost sustained-release intracameral implant in glaucoma. J Glaucoma. 2023;32(9):738–743. doi:10.1097/IJG.0000000000002271
  • Allergan. Durysta (bimatoprost implant) prescribing information. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211911s000lbl.pdf. Accessed October 10, 2023.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.